Shine submits drug master file for Lu-177

By staff writers

August 1, 2022 -- Medical isotope firm Shine Technologies has submitted a drug master file with the U.S. Food and Drug Administration (FDA) for its non-carrier-added lutetium-177 (Lu-177) chloride radiopharmaceutical.

The submission provides confidential and detailed information about facilities, procedures, or articles used in the manufacturing, processing, and storing of drugs, according to the vendor. Shine noted that several companies have requested letters of authorization to access the drug master file in order to support clinical trials underway for cancer treatments.

Copyright © 2022
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking